Faculty

Institution

Unit

Venue

Karen Hoffman

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Radiation Oncology

Department Of Experimental Radiation Oncology

Division Of Radiation Oncology

The University of Texas MD Anderson Cancer Center

Karen Hoffman is a Senior Professor at The University of Texas MD Anderson Cancer Center. Her research focuses on radiation oncology, specifically optimizing treatment for prostate and breast cancers, including hypofractionated radiotherapy and MRI-assisted brachytherapy for recurrent disease. She investigates the genomic and immune impacts of radiotherapy and applies artificial intelligence and deep learning to treatment planning and digital pathology. Her recent work includes a Lancet Oncology meta-analysis of hypofractionation (HYDRA) and a Nature Reviews Urology assessment of AI in prostate cancer, alongside leadership in NRG Oncology trials.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Karen Hoffman

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology radiation oncology prostate cancer urology cancer care radiation therapy cancer treatment radiation breast cancer medicine surgical oncology cancer research prostatic disease clinical radiation oncology cancer imaging surgery cancer management breast oncology genitourinary cancers radiation biology brachytherapy localized prostate cancer outcomes research proton therapy jama oncology nuclear medicine cancer risk androgen deprivation therapy cancer biology patient-reported outcomes clinical trials survival analysis high-risk prostate cancer radiation therapy planning medical physics cancer disparities pharmacotherapy united states radical prostatectomy health care disparities benign prostatic hyperplasia health disparities breast surgery gynecologic oncology medicinal research dosimetry cancer screening neoadjuvant chemotherapy prostate cancer treatment racial disparities thoracic oncology sexual medicine treatment options functional outcomes breast cancer patients urogynecology cancer discovery radiation exposure clinical implementation clinical populations health inequalities executive summary ceasar study randomized trial national trends canadian studies cancer cells clinical evidence health care costs prognosis anti-cancer agents lymphoid neoplasia whole-breast irradiation low-risk prostate cancer dermatological treatment tumor targeting

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer. Clinical Cancer Research (2025)

metastasisradiation oncologybiomedical informaticsprognosisprognostic biomarkersmolecular cancerprostate cancergenitourinary cancersprostatic diseasecomputational pathology modelpredict docetaxel benefitlocalized high-riskurologycancer careoncology

Cancer Risk Concerns and Communication Gaps Regarding Glp-1 Medications. JAMA Network Open (2025)

cancer researchjama oncologymedicinecancer managementpharmacotherapycancer careoncology

Comparison of Outcomes of Microsurgical Breast Reconstruction After Premastectomy and Postmastectomy Radiation Therapy. Journal of the American College of Surgeons (2025)

radiation oncologysurgerymicrosurgical breast reconstructionreconstructive microsurgerymicrosurgerypostmastectomy radiation therapybreast surgeryplastic surgeryreconstructive surgerybreast cancer

Computational Pathology to Predict Docetaxel Benefit for High-Risk Localized Prostate Cancer in Nrg/Rtog 0521 (Nct00288080).. Journal of Clinical Oncology (2025)

Sebastian R. MedinaNaoto TokuyamaKamal HammoudaTilak PathakTuomas MirttiPingfu FuShilpa GuptaPriti LalHoward M. SandlerRohann Jonathan Mark CorreaSusan ChafeAmit I. ShahJason A. EfstathiouKaren E. HoffmanMichael Wayne StrazaMark A. HallmanRichard C. JordanStephanie L. PughFelix Y. FengAnant Madabhushi

biostatisticspathologyprostate cancercancer researchcancer discoverydocetaxel benefittherapeutic efficacycomputational pathologyclinical researchurologyoncology

Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men. Seminars in Radiation Oncology (2025)

clinical radiation oncologyradiation oncologymost mensurgical oncologycombination hormone therapygenitourinary cancersprostate cancerprostatic diseaseurologycancer careoncologydebate 1

Dose Prediction via Deep Learning to Enhance Treatment Planning of Lung Radiotherapy Including Simultaneous Integrated Boost Techniques. Medical Physics (2025)

radiation oncologymedical physicsdeep learningdosimetryradiation therapy planninglung cancertreatment planningdata sciencethoracic oncologyradiationdose predictionmachine learning

Early Outcomes Following Local Salvage Treatment With Mri-Assisted Low-Dose Rate Brachytherapy (Mars) for Mri-Visible Postsurgical Bed Recurrences and Focal Intraprostatic Recurrences. Brachytherapy (2025)

Comron HassanzadehOsama MohamadTeresa BrunoLin WangRajat KudchakarTharakeswara BathalaJeremiah SandersHenry MokSean McGuireDeborah KubanKaren HoffmanQuynh NguyenRyan ParkHoward ThamesPaul CornBrian ChapinSeungtaek ChoiChad TangSteven Frank

radiation therapyradiation oncologylocal salvage treatmentbrachytherapyearly diagnosissurgerymedical imagingsurgical oncologyradiologycancer imagingneuroradiologyfocal intraprostatic recurrencesearly outcomesadaptive radiotherapy

External Beam Radiation Therapy for Salvage After Focal Therapy as Primary Treatment in Prostate Adenocarcinoma.. Journal of Clinical Oncology (2025)

radiation therapyradiation oncologybrachytherapyprimary treatmentprostate adenocarcinomaradiationsurgical oncologyprostate cancercancer imagingfocal therapyurologyoncology

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. Journal of Clinical Oncology (2025)

radiation therapyradiation oncologyrandomized controlled trialsmedical physicsprostate cancerradiologycancer imagingprostatic diseasenuclear medicinephase iiilong-term updateradiationoncology

Hypofractionated Radiotherapy for Prostate Cancer (Hydra): An Individual Patient Data Meta-Analysis of Randomised Trials in the Marcap Consortium. The Lancet Oncology (2025)

Amar U KishanYilun SunAlison C TreeEmma HallDavid DearnaleyCharles N CattonHimanshu R LukkaGregory PondW Robert LeeHoward M SandlerFelix Y FengPaul L NguyenLuca IncrocciWilma HeemsbergenFloris J PosEric HorwitzJessica Karen WongKaren E HoffmanComron HassanzadehDeborah A KubanStefano ArcangeliGiuseppe SanguinetiStephane SupiotGilles CrehangeIgor LatorzeffTahmineh Romero KalbasiMichael L SteinbergLuca F ValleAndrew LoblawJohn NikitasSoumyajit RoyNicholas G ZaorskyAngela Y JiaDaniel E Spratt

radiation oncologyprostate cancermarcap consortiumcancer treatmentoncologyrandomised trials

1
2
3
4
5
34
10 / page

Karen Hoffman

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Radiation Oncology

Department Of Experimental Radiation Oncology

Division Of Radiation Oncology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Karen Hoffman

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer. Clinical Cancer Research (2025)

Cancer Risk Concerns and Communication Gaps Regarding Glp-1 Medications. JAMA Network Open (2025)

cancer researchjama oncologymedicinecancer managementpharmacotherapycancer careoncology

Comparison of Outcomes of Microsurgical Breast Reconstruction After Premastectomy and Postmastectomy Radiation Therapy. Journal of the American College of Surgeons (2025)

radiation oncologysurgerymicrosurgical breast reconstructionreconstructive microsurgerymicrosurgerypostmastectomy radiation therapybreast surgeryplastic surgeryreconstructive surgerybreast cancer

Computational Pathology to Predict Docetaxel Benefit for High-Risk Localized Prostate Cancer in Nrg/Rtog 0521 (Nct00288080).. Journal of Clinical Oncology (2025)

biostatisticspathologyprostate cancercancer researchcancer discoverydocetaxel benefittherapeutic efficacycomputational pathologyclinical researchurologyoncology

Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men. Seminars in Radiation Oncology (2025)

clinical radiation oncologyradiation oncologymost mensurgical oncologycombination hormone therapygenitourinary cancersprostate cancerprostatic diseaseurologycancer careoncologydebate 1

Dose Prediction via Deep Learning to Enhance Treatment Planning of Lung Radiotherapy Including Simultaneous Integrated Boost Techniques. Medical Physics (2025)

radiation oncologymedical physicsdeep learningdosimetryradiation therapy planninglung cancertreatment planningdata sciencethoracic oncologyradiationdose predictionmachine learning

External Beam Radiation Therapy for Salvage After Focal Therapy as Primary Treatment in Prostate Adenocarcinoma.. Journal of Clinical Oncology (2025)

radiation therapyradiation oncologybrachytherapyprimary treatmentprostate adenocarcinomaradiationsurgical oncologyprostate cancercancer imagingfocal therapyurologyoncology

radiation therapyradiation oncologyrandomized controlled trialsmedical physicsprostate cancerradiologycancer imagingprostatic diseasenuclear medicinephase iiilong-term updateradiationoncology

Hypofractionated Radiotherapy for Prostate Cancer (Hydra): An Individual Patient Data Meta-Analysis of Randomised Trials in the Marcap Consortium. The Lancet Oncology (2025)

radiation oncologyprostate cancermarcap consortiumcancer treatmentoncologyrandomised trials

1
2
3
4
5
34
10 / page